Live Rate
| Open | |
|---|---|
| High | |
| Low | |
| Prev. Close | |
| Lower circuit | |
| Upper circuit | |
| 52w High | |
| 52w Low | |
| P/E Ratio |
Listing Price
| Exchange | Listing Price | Gain/Loss | % |
|---|---|---|---|
| NSE | ₹75.00 | +₹3.00 | +4.17% |
Subscription
Last updated on 24-Jun-2025 17:00:23
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 712000 | 2496000 | 3.51 |
| NIB | 604400 | 863600 | 1.43 |
| RETAIL | 1248000 | 2411200 | 1.93 |
| Total | 2564400 | 5770800 | 2.25 |
| Application Wise Breakup | |
|---|---|
| Category | App. Received |
| QIB | 7 |
| NIB | 123 |
| RETAIL | 1507 |
| Total | 1637 |
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIB | 5.13 | 17.97 | 3.51 |
| FII | - | 3.21 | - |
| FI | - | 0 | - |
| IC | - | 0 | - |
| MF | - | 0 | - |
| OTH | - | 14.76 | - |
| NIB | 4.35 | 6.22 | 1.43 |
| RETAIL | 8.99 | 17.36 | 1.93 |
| Total | 18.46 | 41.55 | 2.25 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹0.3 | @8% ₹0.4 | @9% ₹0.4 | @10% ₹0.5 | @11% ₹0.5 | @12% ₹0.6 |
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹0.1 | @8% ₹0.2 | @9% ₹0.2 | @10% ₹0.2 | @11% ₹0.2 | @12% ₹0.2 |
About
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail (10000 to 2 lakh) | 1 | 1600 | 115200 | 780 |
Aakaar Medical Technologies IPO Details
| Issue Size | 37,50,400 shares (aggregating up to ₹27.00 Cr) |
| Fresh Issue | 37,50,400 shares (aggregating up to ₹27.00 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 1,04,22,416 shares |
| Share Holding Post Issue | 1,41,72,816 shares |
| Market Maker Portion | 1,88,800 shares Alacrity Securities Ltd. |
Aakaar Medical Technologies IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Isssue |
Key Performance Indicator (KPI)
| KPI | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROCE | 21.02% | 17.68% | 22.30% |
| D/E | 0.98 | 1.2 | 0.61 |
| RONW | 33.81% | 25.88% | 24.35% |
| EPS (basic) | 6.13 | 3.14 | 2.36 |
| P/E Pre IPO | 12.43 | ||
| P/E Post IPO | 16.9 |
Company Financials In Crores
| Period Ended | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| Assets | 51.9 | 34.0 | 23.2 |
| Revenue | 61.8 | 46.3 | 32.9 |
| Profit After Tax | 6.0 | 2.9 | 2.2 |
| Net Worth | 23.2 | 12.5 | 9.7 |
| Reserves and Surplus | 12.8 | 11.8 | 9.0 |
| Total Borrowing | 22.7 | 15.1 | 5.9 |
About Company
Incorporation: June 2013
Business: Aesthetic medical company specializing in cosmetic products and devices for dermatologists, plastic surgeons, and aesthetic physicians.
Target Clients: Dermatologists | Plastic Surgeons | Aesthetic Physicians | Cosmetologists
Key Business Highlights
Product Portfolio:
Domestically manufactured products.
Internationally produced devices (imported).
Imported Brands: Sourced from South Korea, Spain, Italy, Austria.
Categories:
Skincare: Homecare & professional products.
Injectable & Contouring: Fillers, botox, etc.
Hair Care: Growth serums, anti-hair loss solutions, tablets.
Devices:
Laser hair reduction | Hair transplant devices
Tattoo removal | Skin rejuvenation | Urinary incontinence devices
Medifacial kits
Distribution Model:
B2B Focus: Supplies to clinics/hospitals (doctors resell to end-users or use in treatments).
Consignment Sales Partners: Enables Pan-India reach.
Geographic Presence:
15+ States: Delhi, Haryana, Punjab, Chandigarh, UP, Bihar, West Bengal, Assam, Gujarat, MP, Maharashtra, Karnataka, Telangana, Tamil Nadu.
Branches: Multiple across India.
Team: 90+ trained sales/service engineers → Ensures product support and customer satisfaction.
Strength
Experienced Leadership – Industry-savvy management with deep expertise in aesthetic medicine.
Comprehensive Product Portfolio – Diverse mix of devices and consumables across own and imported brands.
Wide Geographic Reach – Pan-India presence enabled by consignment partners and direct branches.
Weakness
Dependence on Imported Brands – Heavy reliance on third-party imported products exposes the business to supply chain disruptions and foreign market risks.
Contract Manufacturing Risks – Dependence on external manufacturers and loan licensing partners poses risks related to supply continuity, quality control, and compliance.
Cost Volatility – Fluctuations in raw material, utility, and transportation costs can impact profitability and overall financial stability.
Latest Announcements
| Date | Subject | Attachment Text |
|---|
Financial Results
Lead Manager(s)
Address
801, Heritage Plaza,
Telli Galli Cross Road
Andheri (East),
Mumbai, Maharashtra, 400069
Phone: +91 84528 44024
Email: companysecretary@aakaarmedical.in
Website: https://aakaarmedical.in/